A 62-year-old man with diabetes mellitus presents to the emergency department with fever (38.9°C), dysuria, and flank pain of 3 days' duration. Urinalysis shows pyuria and bacteriuria. Urine culture grows a gram-negative rod identified as Escherichia coli. Antibiotic susceptibility testing reveals resistance to ceftriaxone and cefotaxime, but susceptibility to imipenem and meropenem. The organism is ESBL-positive on phenotypic confirmatory testing. The patient is currently on intravenous fluids and empiric cefotaxime. What is the most appropriate immediate next step in management?

Explanation

## Clinical Context This is a case of **acute pyelonephritis** caused by an **ESBL-producing E. coli** with documented **carbapenem susceptibility**. ### Key Microbiological Findings **Key Point:** ESBL-producing organisms are resistant to all β-lactam–β-lactamase inhibitor combinations and third-generation cephalosporins (ceftriaxone, cefotaxime), but remain susceptible to carbapenems (imipenem, meropenem, ertapenem). **High-Yield:** ESBL phenotype = resistance to 3rd-gen cephalosporins + susceptible to carbapenems. This is the diagnostic hallmark. ### Management Algorithm ```mermaid flowchart TD A[Gram-negative UTI/Pyelonephritis]:::outcome --> B{Susceptibility pattern?}:::decision B -->|Susceptible to 3rd-gen cephalosporins| C[Continue cephalosporin]:::action B -->|ESBL-positive<br/>Resistant to 3rd-gen| D{Carbapenem susceptible?}:::decision D -->|Yes| E[Switch to carbapenem<br/>imipenem/meropenem]:::action D -->|No| F[Consider colistin,<br/>tigecycline]:::urgent E --> G[Clinical response<br/>in 48-72 hrs]:::outcome ``` ### Why Carbapenem Now? 1. **Cefotaxime is ineffective** against ESBL-producers despite clinical appearance of susceptibility in some automated systems (major trap). 2. **Carbapenems are the gold standard** for serious ESBL infections because their β-lactam ring is resistant to ESBL hydrolysis. 3. **Pyelonephritis is a serious infection** requiring bactericidal therapy; fluoroquinolones are inferior for upper UTI in septic patients. 4. **No time for repeat culture** — the organism is already identified and susceptibilities are known; delay risks clinical deterioration. **Clinical Pearl:** ESBL-producers can appear susceptible to 3rd-gen cephalosporins on disk diffusion (false susceptibility) due to inoculum effect; always use confirmatory tests (ESBL phenotypic or genotypic) and treat with carbapenems if ESBL is confirmed. **Mnemonic: ESBL-CARB** — ESBL producers = CARBapenem choice. [cite:Harrison 21e Ch 297]